Clinical Trials Logo

Clinical Trial Summary

Recurrent pregnancy loss (RPL) is a refractory disease with diverse etiologies, complex pathogenesis and limited therapeutic options. Current tests and treatments lack uniform specifications. This study is a prospective clinical cohort study which intends to screen out meaningful examination items and reliable and effective treatment. The study content includes (1) tracking the re-pregnancy information of patients with initial inevitable abortion, comparing the clinical data and examination test results between patients with single abortion and RPL, and (2) comprehensively and systematically screening the patients with initial inevitable abortion, taking those without obvious abnormalities and those with a re-pregnancy into the control group and taking those with a re-pregnancy after abnormal findings were treated into the study group, recording the pregnancy and perinatal conditions of the two groups, comparing the pregnancy outcomes of the two groups, and analyzing the risk factors for RPL. The results of this study will establish a model of maternal and newborn risk assessment for first trimester medication use and provide strong evidence-based evidence to clarify the diagnosis and treatment processes of RPL.

Clinical Trial Description

Objective: (1) to establish a prediction model of pregnancy outcome and apply it to clinical practice; (2) to standardize the diagnosis and treatment of RPL. This study is an observational study. The investigators only collect the medical data of patients without any intervention in the diagnosis and treatment plan. The data collection is in the charge of specially-assigned members of the investigators. The investigators set a security password for the database. The data is collected from outpatient medical record system, inpatient medical record system and questionnaire. One investigator is responsible for inputting the data into the database, and another investigator is responsible for checking the Corrigendum. 1. Before enrollment, the investigators would record the medical history of the couple in detail, including age, menstruation, marriage and reproductive history, family history, and the details of previous abortion. 2. The following examinations should be completed before pregnancy: in addition to the routine pre-pregnancy examination items, the examination items related to recurrent spontaneous abortion were added, including uterine artery resistance ultrasound, couple's chromosome, reproductive hormone, OGTT test and some immune related indexes. 3. According to the examination results, the experts of recurrent spontaneous abortion team would evaluate the patients and divided them into: 1) Control group:those who needn't clinical intervention before or after pregnancy , pregnancy was prepared under the clinical and health care guidance provided by experts, and intrauterine pregnancy was confirmed within the study period. 2) Observation group: those who need clinical intervention before or after pregnancy, the experts shall formulate a personalized treatment plan according to the international guidelines. Investigators wouldn't interfere with the expert diagnosis and treatment process. And they should be confirmed intrauterine pregnancy within the study period. (4) The investigators monitored and tracked the indicators during pregnancy and perinatal period of the two groups, including: 1. The participants should complete the routine health care and necessary examination items on schedule, which is the same as that of normal pregnant women. 2. Coagulation function and immune function related tests will be performed respectively in early pregnancy, middle pregnancy and late pregnancy respectively. 3. Length of cervical canal will be check at least once in the second trimester of pregnancy. Uterine artery blood flow was monitored by ultrasound at least every 4 weeks from early pregnancy until 24 weeks of pregnancy. The fetal growth measurement ultrasound was performed respectively at 20 weeks, 28 weeks, 32 weeks and 36 weeks of gestation. 4. Additional OGTT test at 12-16 weeks of gestation. 5. Tests of glucose and lipid metabolism indexes of maternal blood and urine during early, middle and late pregnancy. (5) When the participant is hospitalized for delivery, the investigators will collect the following data: length of hospital stay, diagnosis, fetal position, number of pregnancies, weight gain before delivery, mode of delivery, postpartum hemorrhage, puerperal infection, neonatal birth weight, neonatal Apgar score and examination results during and after delivery. (6) The following analysis shall be made according to the obtained medical data: 1. The statistical differences of various indexes between the two groups were compared. 2. The abortion rate, preterm birth rate and other pregnancy outcomes were compared between the two groups. 3. Multivariate analysis was used to analyze the independent risk factors of recurrent abortion. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05186207
Study type Observational
Source Women's Hospital School Of Medicine Zhejiang University
Status Recruiting
Start date January 12, 2022
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT04718233 - Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss Phase 2
Recruiting NCT01946945 - Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis Phase 2
Completed NCT02572154 - Sperm DNA Fragmentation in Recurrent Pregnancy Loss N/A
Completed NCT03174951 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Phase 2
Active, not recruiting NCT04621773 - Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
Recruiting NCT02990403 - The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss Phase 4
Recruiting NCT02990390 - The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla N/A
Suspended NCT04397042 - SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
Completed NCT02386384 - TNF╬▒ and MFG-E8: Novel Biomarkers to Predict Implantation Failure N/A
Recruiting NCT01635426 - Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages Phase 2/Phase 3
Suspended NCT01546350 - Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH Phase 2
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Terminated NCT00564174 - Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT N/A
Completed NCT04455256 - Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
Active, not recruiting NCT02156063 - A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL) Phase 2
Recruiting NCT02144064 - Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin Phase 3
Withdrawn NCT02379650 - Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss Phase 2
Enrolling by invitation NCT03106935 - Recurrent Pregnancy Loss and Thyroid Disease Early Phase 1
Recruiting NCT03305263 - Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss Phase 3
Recruiting NCT04744025 - Microfluidics Versus Gradient Centrifugation Effect on Euploidy Rates N/A